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Abstract
Dysfunctional mitochondria characterise Parkinson’s Disease (PD). Uncovering etiological molecules, which harm the
homeostasis of mitochondria in response to pathological cues, is therefore pivotal to inform early diagnosis and therapy in
the condition, especially in its idiopathic forms. This study proposes the 18 kDa Translocator Protein (TSPO) to be one of
those. Both in vitro and in vivo data show that neurotoxins, which phenotypically mimic PD, increase TSPO to enhance
cellular redox-stress, susceptibility to dopamine-induced cell death, and repression of ubiquitin-dependent mitophagy. TSPO
amplifies the extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signalling, forming positive feedback, which
represses the transcription factor EB (TFEB) and the controlled production of lysosomes. Finally, genetic variances in the
transcriptome confirm that TSPO is required to alter the autophagy–lysosomal pathway during neurotoxicity.
Introduction
Prevalence of psychiatric symptoms in primary mitochon-
drial diseases are common [1, 2] and debilitating [3]. Sec-
ondary mitochondrial diseases are equally affected, and
Parkinsonism is a vastly acknowledged example [4–7].
Centred around a progressive age-related loss of dopami-
nergic circuits -responsible for bradykinesia and tremor-,
Parkinsonism and PD display non-motor features ranging
from depression, gambling addiction, and dementia. The
symptomatology of PD varies substantially between
patients, with mechanisms that remain ill-defined. One
useful tool to insight those and stratify patients from a
mitochondrial perspective is the Translocator Protein
(TSPO) [8, 9]. This multidrug-binding protein, which is
resident on the Outer Mitochondrial Membrane (OMM),
has been studied for over two decades as a diagnostic
marker of neurotrauma and target for anxiolytic therapy
[10, 11]. Recently, evidence demonstrating the increased
TSPO ligand binding in PD patients [12] made us query
whether the protein had a causal role in the mitochondrial
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dysfunction underlying the condition. Clinical positron
emission tomography (PET) imaging of patients with PD,
dementia with Lewy bodies [13], and progressive supra-
nuclear palsy [14] have revealed a complex but clinically
valuable positive correlation between TSPO and the het-
erogeneous neurological damage [12]. Even though basally
expressed at high levels only within steroid producing tis-
sues [15, 16], TSPO is promptly inducible in cell lineages of
the immune systems, including those residents in the CNS
such as microglia [17–19]. In those, neurological stress
induces a rapid and localised increase in TSPO [20–22].
However, the same occurs in neurons [18, 23–27], mea-
surable via its targeting compounds [8, 19, 28, 29].
Previously we reported that TSPO prevents mitochon-
drial ubiquitination and impairs mitophagy [30], speculating
that this anti-mitophagy function could be replicated in
diseases. Even though PD is multifactorial, the accumula-
tion of defective mitochondria is considered one of its
hallmark [31, 32] driven by impairments in their autophagic
degradation [7, 33, 34]. Studies of the hereditary forms of
PD have indeed unveiled mutations in PTEN-induced
kinase 1 (PINK1) [35] and the RBR E3 ubiquitin protein
ligase Parkin (PARK2) genes [36], associated with a failure
of mitochondrial autophagy as one of the causative
mechanisms [37–39]. However, the PINK1-Parkin pathway
of mitophagy requires potent toxins, like ETC uncouplers
(e.g. FCCP), to be observed in vitro while disposable for
mitophagy in vivo [40, 41]. In addition, recent studies have
suggested physiological functions for the PINK1-Parkin
pathway, which go beyond mitophagy, such as inflamma-
tion [42, 43] and regulation of mitochondrial protein import
[44–46]. The selection and isolation of damaged mito-
chondria from the network require the essential ubiquiti-
nation of OMM proteins to consent their removal via the
autophagosomal-lysosomal pathway [34, 38, 47, 48].
Based on this evidence, we set out to probe whether
neurotoxin-induced mitochondrial damage is associated
with the upregulation of TSPO and deregulation of mito-
phagy. We did so aware that: (i) TSPO expression is driven
by activation of the extracellular signal-regulated protein
kinases (ERKs) [49], and (ii) the mitogen-activated protein
kinase (MAPK)/ERK signalling pathway is a relevant event
during neurotoxicity and particularly PD [50]. The phos-
phorylated form (pERK1/2) is indeed found in Lewy Body
aggregates and autophagosomes of idiopathic PD patients
[51]. Parkinsonian neurotoxins [6-OHDA, rotenone, and N-
methyl-4-phenylpyridinium (MPP+) particularly] induce
ERK phosphorylation following an increase in Reactive
Oxygen Species (ROS), which actively confer neurotoxicity
by inducing cytotoxic autophagy [52] and impairing mito-
chondrial biogenesis [53]. Therefore, activated ERK may
play a role in mediating mitochondrial dysfunction during
PD-like neuronal injury [54] and TSPO high expression
which is indeed driven by ERK [8].
Here, we demonstrate that TSPO is a factor in the
mitochondrial aetiology of neurotoxicity by operating at
multiple levels to impair the autophagosome-lysosomal
pathway triggered by PD toxins. Therefore, TSPO emerges
as a pro-pathological conduit for mitochondria, which
results in several distinctive signatures of the transcriptome.
Materials and methods
Animal experiments
6-OHDA lesioned rat brain sections for immunohistological
analysis were prepared as previously described [55]. Briefly,
the rats (male, Sprague Dawley, 250 ± 25 g, Harlan, UK)
were group-housed at standard conditions, and all experi-
ments were conducted under the Home Office Animals
(Scientific procedures) Act, UK, 1986 and were approved by
the King’s College London ethical review committee (pro-
ject licence P023CC39A, D Cash). The lesioning with 6-
OHDA was achieved by stereotaxically administering 12 µg
of 6-OHDA into the medial forebrain bundle. The success of
lesioning was verified by apomorphine-induced rotations
(>100 in 60 min), and the animals sacrificed 3 weeks after 6-
OHDA by transcardiac perfusion and fixation with hepar-
inised saline, followed by 4% buffered paraformaldehyde.
PET imaging was carried out on a separate set of animals in
a separate facility. Male Sprague-Dawley rats (Charles
River, UK) weighing ca. 250 g, were housed in groups of
three per cage under a controlled temperature (21+ 1 °C),
relative humidity (60%) and a 12 h light/dark cycle, with
access to food and water ad libitum.
Surgery and imaging
Under recovery anaesthesia (isoflurane), rats were injected
with 6‐OHDA. Twelve µg 6‐OHDA free base in 4 µl 0.1%
ascorbic acid in 0.9% saline (n= 4) or vehicle (control
n= 2) was injected stereotactically [56] into the left medial
forebrain bundle (mfb) (−2.2 mmA/P, +1.5 mm L/M
coordinates from bregma; −7.9 mm D/V from dura), as
previously described by the authors [57]. Nine days post-
lesion rats received an i.v. bolus of [11C]PBR28. Subse-
quently, two of the four lesioned rats underwent a PET:CT
scan. [11C]PBR28 was prepared by 11C-methylation of the
corresponding O-desmethyl precursor using [11C]methyl
iodide. The specific activity was 289 GB q/umol. For ima-
ging studies, the femoral vein and artery of SD rats were
cannulated under terminal isoflurane anaesthesia prior to
[11C]PBR28 administration. A dynamic PET:CT scan
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(INVEON DPET/MM PET:CT, 60 min) was carried out
and reconstructed with 2D FBP (CT attenuated with scatter
correction). Blood samples were collected to obtain a
metabolite-corrected input function. Regions of interest
(ROI) were drawn on the lesion site and an equivalent
contralateral area. Time activity curves (TACs) were
derived, and the volume of distribution (VT) was estimated.
After 60 min, all rats were exsanguinated; blood and plasma
were collected, and brain regions were removed and washed
in chilled saline, and the associated radioactivity was
determined in all samples by a gamma counter. For [3H]
PBR28 radiography, striatal and substantia nigral sections
(4.52–4.80 mm from Bregma) were cut onto poly-l-lysine
coated slides and incubated with 0.5 nM [3H]PBR28 for
60 min. To determine non-specific binding, slides were
incubated with 0.5 nM [3H]PBR28 with an excess of 10 µM
PK11195 for 60 min. Slides were washed and allowed to
dry in a cool stream of air. Slides were covered by a scin-
tillation sheet and counted for 24 h per slide. Quantification
of the autoradiography images was carried out using Ima-
geJ, by comparing the values extracted from each ipsilateral
hemisphere to respective contralateral Control. Each image
was separately assessed using the Max Entropy algorithm in
the area of pixels above threshold.
Cell culture and transfection
SH-SY5Y cells were obtained from ATCC and were main-
tained in Dulbecco’s Modified Eagle’s medium (DMEM)
(Thermo Fisher, 11995073) supplemented with 10% Foetal
bovine serum (FBS) (Thermo Fisher, 10082-147) and 1%
penicillin/streptomycin (P/S) (Thermo Fisher, 15140122). To
induce differentiation, a serial treatment combination of
reduced medium (DMEM+ 0.5 % FBS and 1 % P/S) for
10 days, with the first 3 days in 15 μM retinoic acid (RA;
Sigma, R2625) and the successive 7 days of 0.5 ng/mL BDNF
(Sigma, B3795). Transfection was carried out using a standard
Calcium (Ca2+) phosphate method, as described previously
[58]. In experiments containing +TSPO and −TSPO condi-
tions together, the RNAi samples (nsc and −TSPO) were
normalised to the mean of the mock transfected samples.
Treatments were initiated 48 h post-transfection. Plasmid
transfection was used to induce expression of exogenous
proteins, over-expression of selected proteins or down-
regulation of TSPO via RNA interference (SI02777061, Qia-
gen; sense: CAUCUUCUUUGGUGCCCGATT; antisense:
UCGGGCACCAAAGAAGAUGGG). Plasmid list: scram-
bled RNA (scrRNA) (1027281, Qiagen), non-silencing control
(nsc); mTSPO - pCR™ 2.1-TOPO® TA vector with gene
D21027, Parkin-YFP (Addgene, 23955), LC3-GFP (Addgene,
210730), ubiquitin-GFP (Addgene, 11928), CFP (Addgene,
1179), GFP (Addgene, 1150), mtGFP – generous gift from
Prof Rizzuto, mtRFP (Evrogen, FP147), dsRed (Addgene,
11151). Stable TSPO knockdown was achieved using the
pGIPZ shRNA vector: clone ID V3LHS_331646, target
sequence: 5′-TGAGTGTGGTCGTGAAGGC-3, purchased
from Open Biosystems (Huntsville, AL, USA). Non-silencing
shRNA vector sequences (mature antisense): V3LHS_331648:
5′-ACGCAGTAGTTGAGTGTGG-3′ V3
LHS_331650: 5′-TCTGCAGGCCGGCGTACCA-3′. After
transfection, cells were maintained for 2 weeks in media
supplemented with 3 μg/ml puromycin (SERVA Electro-
phoresis GmbH) to select transfected (GFP-positive) cells.
TSPO KO SH-SY5Y cells were generated by transient
transfection with GeneArt™ CRISPR Nuclease Vector with
OFP Reporter Kit (Thermo Fisher, A21174), using a gRNA
(5′-GGGCACGCTCTACTCAGCCA-3′) targeting exon 2.
Fibroblasts were obtained from Coriell Cell Repository (cor-
iell.org) via MTA with HM; patient samples and Control
samples were age-and sex-matched (details given in Table 1).
Fibroblasts were cultured and maintained in EMEM (Gibco)
as previously described [59]. Fibroblasts were passage mat-
ched for experiments and used between passages 10 and 15.
Immunocytochemistry
Cells were initially plated on 22 mm glass coverslips at a
30% confluency and collected 48–72 h after transfection. At
treatment completion, cells were washed once with 0.01M
Phosphate Buffered Saline (PBS 1X) and fixed with 4%
paraformaldehyde (PFA) with a 10 min incubation. Cells
were then washed three times for 5 min each with PBS 1X
and permeabilised with a 0.5% Triton-X100/PBS 1X solu-
tion for 10–20 min. After another round of washes, cells
were blocked for 1 h in a solution of PBS 1X containing
10% v/v goat serum (Thermo Fisher, 16210064) and 3%
w/v BSA. Primary antibody was incubated overnight at
4 °C in blocking solution at the following concentrations:
1:250 ATP5B (Abcam, ab14730), 1:250, TFEB (Cambridge
Table 1 The table details the information on the participant samples
used for this study.
Code Status Mutation Age at
biopsy (yrs)
Sex
GM02189 Control 63 M
GM029510 Control 55 F
GM09400 Control 61 F
GM07924 Control 52 M
ND31618 Parkin mutant ARG42PRO 63 F
ND30171 Parkin mutant ARG42PRO/
EX3DEL
54 M
ND40078 Parkin mutant ARG275TRP/
ARG275GLN
51 F
ND37732 Parkin mutant EX3 40 BP DEL/
EX4DEL
63 F
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Bioscience, A303-673A) or 1:100 Tau (Abcam, ab32057).
After three washes, the secondary antibody was incubated
for 1 h at a 1:500 dilution of the following secondary
antibodies in blocking solution: anti-mouse goat IgG Alexa
488 (Abcam, A11001), anti-rabbit donkey IgG Alexa 568
(Abcam, A10042), anti-mouse goat IgG Alexa 633 (Abcam,
A21050). After 1 h at room temperature away from light,
the coverslips were washed and mounted onto glass slides
using a 4′,6′-diamidino‐2-phenylindole (DAPI)-containing
mounting medium (ab104139). The coverslips were then
imaged on a Leica SP5 confocal microscope.
Western blotting
Lysates were either made from mitochondrial fractions and
whole cells. Fractions were collected in sucrose buffer
(50 mM sucrose, 10 mMKCl, 20 mM HEPES, 1.5 mM
MgCl2, 1 mM EDTA, 1 mM EGTA [Sigma, E8145], pro-
tease inhibitor [Roche, 4693132001], pH 7.4) on ice. To
break the plasma membrane, the cell suspension was passed
through a 26-gauge needle (Sigma, Z192392) ~30 times.
Separation of the mitochondrial and cytoplasmic fractions
was performed using differential centrifugation, as shown
previously [60]. Primary antibodies: ACTB (Abcam,
ab8826) 1:5000, ATP5B (Abcam, ab14730) 1:5000, ERK1/
2 (Cell signalling, 9102S) 1:1000, pERK1/2 (Y202/Y204)
(Cell signalling, 9101) 1:500, SDHA (Abcam, ab109865),
TSPO (Abcam, ab109497) 1:4000, USP30 (Enzo, MBL-
PW0975) 1:1000, VDAC1 (Abcam, ab14734) 1:2000,
1:10000 Vinculin (Abcam, ab129002) and 1:1000 TFEB
(Cambridge Bioscience, A303-673A). Imaging was carried
using an ECL based method (GE, RPN2133) on a a Bio-
Rad ChemiDoc MP Imaging System, following incubation
for 1 h with either anti-rabbit conjugated HRP 1:4000
(Dako, P0447), or rabbit anti-mouse conjugated HRP
(Dako, P0448), or goat anti-rat IgG conjugated HRP 1:4000
(Abcam, ab97057). Densitometric analysis was performed
using the ImageJ software. Values were normalised to
ACTB loading control for whole-cell lysates and ATP5B
for mitochondrial fractions.
Immunohistochemistry
Following PBS washing, slices were incubated at 80 °C for
30min in citrate buffer: 10mM sodium citrate dehydrate
(Sigma, W30200), 0.05% Tween‐20 (Sigma, P7949), pH 6.0.
Washes were followingly carried out in PBS-T (0.05% Tween-
20 in PBS). Permeabilization was carried out for 15min at 4 °C
in 20mM HEPES, 300mM sucrose (Sigma, 59378), 50mM
NaCl, 0.05 % Triton‐X100 (Sigma, T8787), 3mM MgCl2,
0.05% sodium azide (Sigma, 71290). Blocking – 1 h at room
temperature in 10% horse serum (Thermo Fisher, 16210064),
1% w/v bovine serum albumin (BSA) (Sigma, A2153) in PBS
1X. Primary antibody incubation was carried out overnight at
4 °C first using a 1:150 dilution of rabbit TSPO antibody
(biorbyt, orb5845) and the next day, after washing, using rat
DAT antibody (Millipore, MAB369), 1:150 in blocking solu-
tion. Secondary antibodies: anti-rat goat IgG Alexa 555-
conjugated (abcam, ab105158), anti-rabbit goat IgG Alexa
488-conjugated (Invitrogen, A11008) at 1:200 in blocking
solution for an hour at RT, while shaking. Slices were washed
4–5 times in PBS-T 1X and three times in PBS 1X, before a
5min incubation with 600 nM DAPI solution (D1306, Invi-
trogen). Excess DAPI was cleared with three 5min washes in
PBS 1X and slices were then mounted on glass slides (VWR,
631-0908) using a polyvinyl alcohol mounting medium con-
taining 1,4-diazabicyclo[2.2.2]octane (DABCO®) (Sigma,
10981), covered with 22mm glass coverslips. The slices were
then imaged on a confocal Leica SP5 with a 63x lens. TSPO
intensity was gathered from DAT stained projections within the
globus pallidus and entopeduncular nucleus of multiple stained
slices (n= 3). Equal numbers of neurons from each slice and
each area were compared.
Quantitative PCR
Quantitative reverse-transcription PCR (qRT-PCR) was
carried out with a standard calibration curve containing
serial dilutions of each cDNA transcript for each separate
gene. The mRNA isolation step was carried out using the
RNeasy Plus Mini kit (Qiagen, 74134), as per manu-
facturer’s instructions. cDNA synthesis was carried out
using the QuantiNova™ Reverse Transcription Kit (Qiagen,
205411), in an RNase-free environment. Only RNA sam-
ples with 260/280 nm of 2.0 ± 0.2 were used. Real-time
PCR, executed with the QuantiNova SYBR Green PCR kit
(Qiagen, 208052), was used to amplify the standards and
then quantify the sample’s mRNA expression. Using 96-
well PCR plates (Thermo Fisher, AB0800W), covered by
adhesive seals (4titutde, 4ti-0565), triplicates of each sam-
ple were mixed with SYBR green dye and appropriate
primers. Details: MAOB (proprietary, qHsaCID0017743),
TSPO (proprietary, qHsaCED0037846), USP30 (S: GGG
ATTATAGACCGGACACTA, AS: CACAAGCCCTTTT
CTACGCT); 18S (S: CGCGGTTCTATTTTGTTGGT, AS:
AGTCGGCATCGTTATGGTC). The 96-well plate was
placed into a CFX Connect™ Real-Time PCR Detection
System, and 40 cycles of denaturation (5 s, 95 °C) and
extension (10 s, 60 °C) were executed.
Redox analysis
Dynamic analysis of cellular redox was carried out using
four different live cell imaging dyes, that detect specific
molecular species: cytoplasmic superoxide is analysed
using DHE (Life Technologies, D11347); mitochondrial
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superoxide is detected with mitoSOX™ Red (Life Tech-
nologies, M36008); global cellular hydrogen peroxide
(H2O2) and peroxyl radicals (HO2) are measured using
DCFDA (Sigma, D6883) while unbound reduced glu-
tathione (GSH) is assayed with MCB (Life Technologies,
M-1381MP). Cells were cells co-transfected with an
appropriate fluorophore that would not interfere with the
fluorescence of the dye. All dyes were administered to the
recording medium (RM) onto cells plated on coverslips,
within Attafluor® metal cell chambers (Molecular Probes™,
Thermo fisher, A-7816). RM composition is: 5.6 mMKCl
(Sigma, P9333), 10 mM D-(+)-Glucose (Sigma, G7528),
10 mM HEPES (Sigma, H4304), 4.2 mM NaHCO3 (Sigma,
56297), 138 mM NaCl (Sigma, S5886), 2.6 mM CaCl2
(Sigma, C7902), 1.2 mM NaH2PO4 (BDH,1024940),
1.2 mM MgCl2 (BDH, 10149), pH 7.4.
DHE (10 μM), mitoSOX (10 μM), and DCFDA (15 μM)
were diluted in RM and imaged onto a Zeiss LSM510 con-
focal microscope. MCB was used at final concentration of
2.5 μM in RM. Brightness controlling settings were main-
tained consistently within the experiment for all techniques.
mtKeima measurement
To analyse the delivery of mitochondrial content to the
lysosome, we used a plasmid vector expressing mt-Keima
([Amalgaam, AM-V0251]). Cells were transfected with
mtKeima, treated, and successively imaged on a Leica SP5
microscope while in RM buffer at 37 °C. Using ImageJ,
ratio pictures of 586/440 nm excitation were created, and
the number of pixels emitting only red signal over the total
number of pixels per cell was used as mitophagy index.
Imaging of mitochondria
To image the lysosomal population, cells were transfected
with DsRed and TSPO siRNA/nsc, treated in culture media,
stained with 100 nM LysoTracker™ DND-22 (Thermo Fisher,
L7525) for 30min and then imaged on a Leica SP5, in RM.
Their number or volume was quantified on ImageJ, using the
“3D object counter” plugin. Mitochondrial morphology was
assayed using cells transfected with a mitochondria-targeted
GFP (mtGFP), utilising only cells with neurites. Aspect Ratio
(AR), a measure of elongation, and Form Factor (FF), the
inverse of circularity and a measure of branching, were cal-
culated on the whole mitochondrial network, with ImageJ
software. ΔΨm was measured using tetramethylrhodamine
methyl ester (TMRM). Fluorescence intensity was directly
measured after incubation of 50 nM TMRM in RM for 30min
on a Zeiss LSM510 confocal microscope. To measure basal
membrane potential, only mitochondrial ROIs were used,
while the rate of MPP(+)-induced depolarisation was mea-
sured using live recordings of whole-cell ROIs.
Transcriptome data analysis
Using the CRISPR/Cas9 system, we generated a line of
SHY-SY5 ablated for TSPO gene (SHY-TSPO KO). This
and the control line were exposed to MPP+ before
extracting the total RNA. Total RNA samples from TSPO
WT and KO cells were extracted using TRIzol reagent
(Invitrogen; 374 Thermo Fisher Scientific, Waltham, MA,
USA) and then quantified with an Agilent 2100 bioanalyzer.
The quantified RNA samples were used for NEBNext®
rRNA-depleted (Human/Mouse/Rat) stranded library pre-
paration. Library preparation and RNA sequencing was
conducted at the UCL Genomics. Libraries were prepared
using non-strand specific Illumina TruSeq Sample Pre-
paration Kits followed by Illumina sequencing. FASTQ
files were aligned using TopHat and Cufflinks. Normal-
isation and differential analyses were carried out using R
software Bioconductor [61] package DESeq2 [62], and gene
set enrichment analysis (GSEA) was carried out using
EGSEA [63].
Assessment of cell viability
Cell viability was measured using propidium iodide (PI,
Sigma, P2667-2OTST). Cells were co-transfected with GFP
in six well plates. After treatment, wells were washed with
PBS once and successively incubated for 10 min with 3 µg/
ml of PI in RM. Three washes with PBS were used to
remove excess stain. The cells were then maintained in RM
and imaged immediately using the Leica DMIRB inverted
fluorescence microscope. The proportion of PI-positive cells
within the transfected population was used as a measure of
viability. The trypan blue exclusion method (100, 300 µM,
Sigma) was also enrolled, and cells counted under the
KOVA® Glasstic Slide with Counting Grids.
Data analysis
Data are presented as mean ± standard error of the mean.
Statistical analysis was performed using R software (version
3.0.2). All analyses were carried out in a standardised
manner. In summary, to determine whether the sample
distributions were normal, a Shapiro–Wilk test was per-
formed for sample groups with N < 50; for sample groups
with N ≥ 50, a histogram and a quantile-quantile were
employed. For experiments with two normally distributed
conditions, a Welch’s t-test was performed. If the experi-
ment included multiple conditions, a one-way analysis of
variance (ANOVA) tests was performed to address if the
variance between samples was smaller than between con-
ditions, (i.e. vehicle-treated ± TSPO cells to MPP+ treated).
Comparisons between conditions were carried out using a
pairwise t-test, utilising Holm’s correction. If any sample
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failed the normality distribution tests, a Wilcox test was
used to compare two conditions, a Kruskal–Wallis test was
used to compare groups of conditions and a Wilcoxon rank
sum tests with Holm’s multiple correction for pairwise
comparisons. The N numbers utilised indicate the number
of biological repeats. In assays that compare bulk groups of
cells, i.e. WB or cell viability, 3 or 4 separate sets of
experiments (and treatments) were compared, with technical
repeats (multiple measurements of the same biological
sample) averaged out. In imaging experiments, two separate
treatments and transfections were carried out, and the
number of cells analysed per condition is reported as N. In
the PET and autoradiography experiments, the N number
indicates the total number of animals used per condition.
Statistical significance is indicated as follows: ‘*’ – p < 0.05;
‘**’ – p < 0.01; ‘***’ – p < 0.001.
Results
TSPO expression increases in Parkinson’s disease
Our analysis began by assaying the accumulation of TSPO
in vivo using second-generation ligands for the protein in a
PD rat model. Animal brains were scanned via PET 9 days
after unilateral injection of 6-OHDA. Based on the data
collected, a heat map representing the binding of the radi-
olabelled, high-affinity [16, 29] TSPO ligand [11C]PBR28
was generated (Fig. 1A). This effect was quantified via
biodistribution analysis (Fig. 1B), indicating a marked
upregulation of [11C]PBR28 uptake in the brains of 6-
OHDA-injected animals when compared to the sham-
injected group. Moreover, the extent of [11C]PBR28
uptake after 6-OHDA injection was significantly higher in
the ipsilateral brain hemisphere of treated animals than in
the contralateral one. Further analysis of coronal sections of
the central nervous system (CNS) of rats subjected to the
same treatment was run via autoradiography, using radi-
olabelled PBR28 (Fig. 1C). The quantification in 1D
showed a generalised increase in radioactive signal in the
ipsilateral hemisphere of 6-OHDA-injected animals, con-
firming the PET’s trend observed previously. Even though
the accumulation of TSPO is commonly acknowledged to
be occurring in glial and microglial cells, neurons can
express the protein too (Fig. 1E) [64]. In order to test if
dopaminergic neurons can upregulate TSPO following
treatment with neurotoxins, we carried out an immunohis-
tological analysis of coronal brain sections of 6-OHDA-
treated rats (n= 3). Different midbrain sections were
selected, labelled with the nuclear stain 4′,6-diamidino-2-
phenylindole, dihydrochloride (DAPI), and an immu-
noassay was run for TSPO and dopamine transporter (DAT)
[65–67] (Fig. 1F, G). By looking at the globus pallidus and
the entopeduncular nucleus, we found that dopaminergic
neurons revealed a predominant co-localisation between
TSPO and DAT-positive, and following treatments with the
neurotoxins, TSPO was markedly overexpressed (Fig. 1F,
G). Validation of TSPO upregulation in PD rat models and
its neurotoxin-induced accumulation in dopaminergic neu-
rons represented the basis for the next in vitro set of ana-
lyses, which began by exposing SH-SY5Y cells to 6-OHDA
(50 μM, 4–8 h) and measuring TSPO levels via Western
blotting (WB) (Fig. 1H, I). The analysis corroborated
the results obtained both in vivo (Fig. 1A, B) and
ex vivo (Fig. 1F, G). To further the relationship between
PD-related mutations and increased TSPO expression,
fibroblasts from PD patients (n= 4) bearing point mutations
and/or exon deletions on the PARK2 gene (Table 1) were
characterised by significant TSPO over-expression when
compared to age-and-sex-matched controls. (Fig. 1J–L).
TSPO upregulation is the result of an ERK1/2-
dependent transcriptional response
Having observed that SH-SY5Y cells recapitulate the
upregulation of TSPO observed in vivo, we administered
two other PD-linked neurotoxins, chosen for their ability to
induce ERK-dependent autophagy and Parkinsonism
in vivo [68–71] (Table 2). By administering rotenone (Rot)
(100 nM), we monitored the level of TSPO over time (4, 6,
and 8 h) (Fig. 2A, B). The results showed that the increase
in the expression of TSPO was achieved already at 4 h of
treatment, and there were no significant differences between
the time points tested (Fig. 2A, B). The second neurotoxin
used, MPP+, had shown a more pronounced increase,
compared to Rot, in TSPO previously [72–75], at a con-
centration of 0,5 mM in 8 h; therefore, we focused our
subsequent analyses on this neurotoxin. The activation of
ERK1/2 induces TSPO transcription via activator protein 1
(AP1) and signal transducer and activator of transcription 3
(STAT3).
To assess whether MPP+induced upregulation of TSPO
expression was dependent on ERK1/2, we treated the cells with
U0126 (5 μM, 8 h), a pharmacological inhibitor of mitogen-
activated protein kinase (MEK)-induced ERK1/2 phosphor-
ylation. As shown in Fig. 2C, D, the co-administration of
U0126 prevented the upregulation of TSPO in response to
MPP+. At confirmation of the MPP+dependent increase of
TSPO transcription, mRNA levels were assessed via qRT-PCR
(Fig. 2E). SH-SY5Y cells were treated for a longer time (20 h),
and the results showed a significantly higher expression of
TSPO mRNA levels than untreated cells (Fig. 2E). Then we
tested the effect of MPP+ (0.5mM) at 8 and 20 h, looking at
different mitochondrial proteins (Fig. 2F–H). Remarkably, the
inner mitochondrial membrane proteins ATP synthase
(ATP5B) and succinate dehydrogenase complex (SDHA)
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remained substantially unchanged (Fig. 2F–H). Perhaps
unsurprisingly, the OMM protein voltage-dependent anion
channel (VDAC1), to which TSPO is molecularly and func-
tionally linked [60, 76, 77], increases its expression after 20 h
of treatment by an average of 20% (Supplementary
Fig. 1A–D). The hypothesis whereby the accumulation of
TSPO represents a pro-pathological mechanism was corrobo-
rated further by the degree of cell death in SH-SY5Y in
response to MPP+ using dosages (Fig. 2J, K) equally able to
collapse the mitochondrial membrane potential (ΔΨm) (Sup-
plementary Fig. 2A–F). A low but sustained dose of the MPP+
damaged cells expressing TSPO (Control and +TSPO),
L
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leaving unharmed those in which the protein was down-
regulated (-TSPO) (Fig. 2J). An opposite outcome was mea-
sured with the administration of MPP+ at a higher con-
centration, which was detrimental for neurons devoid of TSPO
(Fig. 2K). Such an observation on cell death susceptibility was
expanded further by using dopamine in toxic concentrations
(100, 200, and 300 µM) and confirmed in differentiated SH-
SY5Y cells (Fig. 2L).
TSPO shifts the cellular redox balance of neurons
Subsequently, we adopted live-cell imaging tools to monitor
different subcellular pools of ROS in SH-SY5Y cells mock-
transfected (Control), transiently over-expressing TSPO
(+TSPO) or down-regulated for the protein (-TSPO).
We initially administered MPP+ in acute exposure (4 mM,
15 min) to cells loaded with dihydroethidium (DHE), which
allows measuring the cytoplasmic pools of superoxide.
Figure 3A–C showed that, at steady state, cytoplasmic O2
●-
is heightened solely in +TSPO cells, with levels that are
comparable to control cells after MPP+ treatment. While
control cells underwent an increase in signal following
MPP+ administration, −TSPO cells did not show any
relevant change. By using the mitochondrially targeted,
superoxide indicator MitoSOX™ (mitoSOX) as a read-out
of mitochondrial ROS (mROS) (Fig. 3D, E), we instead
observed that basal mitoSOX fluorescence emission was
almost doubled in -TSPO cells when compared to control
conditions, and that acute treatment with MPP+ (4 mM,
15 min) lowered its intensity. Oppositely, the over-
expression of TSPO (+TSPO) counteracted the MPP+
increase in mitoSOX fluorescence (Fig. 3D, E). Analysis of
global cellular hydroxyl radicals using 2ʹ,7ʹ-Dichloro-
fluorescin Diacetate (DCFDA) fluorescence showed the
same trend observed with DHE (Fig. 3F, G). And thus,
-TSPO cells display significantly lower accumulation of
DCFDA fluorescence than Control or +TSPO cells and are
protected from MPP+induced increase in ROS levels.
Control cells showed instead a statistically significant
increase in global cellular hydroxyl radicals after acute
treatment with MPP+ which is ineffective on +TSPO cells
which feature a more oxidised basal redox balance at resting
conditions. To monitor the effect of TSPO modulation on
the antioxidant capacity of SH-SY5Y cells, we then ana-
lysed reduced GSH levels via monochlorobimane (MCB).
The results showed that +TSPO cells are highly sensitive to
the MPP+-induced generation of ROS, which causes a
significant drop in the pool of reduced GSH that was not
observed in either Control or -TSPO cells (Supplementary
Fig. 1E–G). To further address the opposite relationship
between cytoplasmic and mROS pools, we used superoxide
scavengers to remove, selectively, ROS from each intracel-
lular compartment. By employing the artificial antioxidant
TEMPO or its mitochondrially targeted version: mito-
TEMPO, we measured the compartment-specific pools of
oxidised GSH, interpolated from the increase in MCB signal
following scavenger treatment (Supplementary Fig. 1H).
This revealed that -TSPO cells had oxidised GSH in both
compartments, while +TSPO cells only in the mitochondria.
In addition, mitoTEMPO does not shield +TSPO cells, like
TEMPO, we infer that these cells are very susceptible to
MPP+induced ROS in the cytoplasm.
Knowing that TSPO engages the Ca2+-dependent
NADPH oxidases (NOX) [60, 78] to generate ROS, we
tested whether monoamine oxidases (MAOs) [79–81] were
involved in this redox rewiring. A qRT-PCR analysis
revealed that +TSPO cells present vastly increased levels of
MAOB (Fig. 3H). Finally, the pro-oxidant phenotype
induced by TSPO over-expression is paired with a dis-
organised and dense mitochondrial network, which is more
elongated and branched in -TSPO cells. However, TSPO
depletion predisposes mitochondria to undergo a drastically
more severe fragmentation after exposure to MPP+
(Fig. 3J, K). Therefore, TSPO over-expression induces an
imbalance in redox production, which is likely to promote
toxicity by neurotoxins leading to the assessment of mito-
phagy response in these conditions.
The upregulation of TSPO de-ubiquitylates
mitochondria
Mitophagy can function as a quality-control stress response to
remove damaged mitochondria. It can be induced by a variety
Fig. 1 In vivo and in vitro upregulation of TSPO by Parkinsonian
toxins. A A representative PET image of [11C]PBR28 uptake in the
brain of a Sprague-Dawley rat subjected to a unilateral injection of 6-
OHDA for 9 days. Yellow arrows indicate representative areas of high
uptake; the stereotaxic drill hole is indicated in the sagittal view by a
blue arrow. B Bar charts displaying the average [11C]PBR28 uptake in
the whole hemisphere of 6-OHDA lesioned rats (n= 5), with con-
tralateral control hemisphere, and of sham samples (n= 3), subjected
to an injection of saline. C Representative autoradiography section of
unilateral 6-OHDA lesioned rats displaying [3H]-PBR28 uptake, with
a (D) threshold-based image quantification of [3H]-PBR28 signal
comparing whole ipsilateral to contralateral hemispheres. E Compar-
ison of TSPO expression in endothelial, microglia, neuron, and
astrocyte tissues using a public mRNA database [64]. F Representative
immunohistological images of coronal sections (contralateral and
ipsilateral origin) of the 6-OHDA-treated rats stained for DAPI, TSPO,
and DAT. G Image-based quantification of co-localised TSPO signal
intensity in DAT-stained neurons from different midbrain sections
(n= 10 cells per condition). H Representative bands of WB of TSPO
and loading control ACTB in whole SH-SY5Y cell lysates, under the
administration of 50 µM 6-OHDA for 4 or 8 h, with, in (I), its ACTB-
normalised band density (n= 4). J Representative image from a SDS-
PAGE analysis of TSPO expression, controlled against ACTB and the
mitochondrial VDAC1, in fibroblasts of Parkin mutant PD patients,
with respective age-&-sex-matched controls. Band density quantifi-
cation of TSPO expression normalised (K) the loading control ACTB
and (L) to the mitochondrial control VDAC1 (n= 4).
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of toxic or non-toxic triggers [82] and be carried out by dif-
ferent pathways [83]. Within the context of neurodegenera-
tion, the PINK1-Parkin pathway has been linked more
strongly to pathology and studied at highest depth [7].
However, previous studies showed an activation of Parkin-
independent mitophagy following neurotoxin addition
[70, 71, 84, 85]. Therefore, we monitored the steps of the
mitophagic cascade in response to MPP+. We began by
enrolling the mtKeima reporter, which measures mitochon-
drial delivery to lysosomes, comparing Control, +TSPO, and
−TSPO SH-SY5Y cells (Fig. 4A). TSPO downregulation
induced a significant increase in mitophagy index both at
resting conditions and after MPP+ treatment, while TSPO
overexpression induced the opposite but less pronounced
phenomenon. Oppositely, the mitochondrial uncoupler car-
bonyl cyanide-4-(trifluoromethoxy) phenylhydrazone
(FCCP), commonly used to activate PINK1-Parkin-mediated
mitophagy, induced a robust and comparable increase in
mitophagy index in Control and -TSPO cells, but a strong
reduction caused by TSPO overexpression. Notably, the MPP
+induced increase in signal was quantified as being 30–50%
that of FCCP-treated cells (Fig. 4A).
To confirm the involvement of the autophagy pathway in
response to MPP+ treatment, we measured autophagosome
and Parkin recruitment on mitochondria in SH-SY5Y cells
expressing the fluorescent reporters LC3-GFP (Fig. 4B, C)
and Parkin-YFP (Fig. 4D, E), calculated as a number of
mitochondrial LC3 punctae, or mitophagosomes, per cell.
Bafilomycin 1A (BAF) (10 nM), an inhibitor of the vacuolar-
type H(+)-ATPase, was used to block lysosomal acidification
and prevent autophagic degradation [86], therefore allowing
the accumulation of the mitophagosomes. Both analyses
demonstrated that MPP+ treatment does not block the
translocation of Parkin on mitochondria. Therefore, in order
to gain insights into the mechanism via which TSPO inhibits
mitophagy during MPP+ treatment, we assessed the levels of
mitochondrial ubiquitination in Control and TSPO SH-SY5Y
cells by measuring the degree of co-localisation between
ATP5B and ubiquitin. Notably, repression of TSPO activity
increased basal levels of mitochondrial ubiquitination (Sup-
plementary Fig. 3I–L), which were increased further when
BAF was combined with MPP+ (Fig. 4F, G). Oppositely,
TSPO over-expression, simulating the upregulation seen after
treatment, increased the level of the deubiquitinase (DUB)
ubiquitin specific peptidase 30 (USP30), as shown both via
WB (Fig. 4H, I) and a qRT-PCR analysis (Fig. 4J). USP30 is
the sole mitochondrially localised DUB [87] that impairs
basal [88] and Parkin-mediated mitophagy [46]. Its inhibition
has been proven to induce basal mitophagy upstream of
PINK1, without inducing Parkin translocation [88]. To con-
firm the engagement of USP30 in the mitophagy pathway
inhibited by TSPO, we transfected PINK1 KO SH-SY5Y
cells (Fig. 4K) with mtKeima and measured the number of
mitochondria removed by lysosomes in the presence and
absence of TSPO (Fig. 4L). As expected, we observed an
abolishment of the pro-mitophagic effects of TSPO inter-
ference, alongside the absence of any effect induced
by FCCP.
Nevertheless, MPP+ generated a significant increase in
the mitophagy index of control cells, indicating that, in the
presence of TSPO, the neurotoxin induces mitochondrial
delivery to lysosomes without engaging the PINK1-Parkin
Table 2 The table shows the three Parkinsonian neurotoxins used in the study, their chemical structures and their neurotoxic properties.
Acronym Name Chemical structure Neurotoxicity
6-OHDA 6-hydroxydopamine It is an hydroxylated analogue of dopamine
rotenone rotenone Inhibits the transfer of electrons from iron-sulfur
centers in complex I to ubiquinone
MPP+ 1-methyl-4-phenylpyridinium Interferes with the oxidative phosphorylation in
mitochondria by inhibiting complex I
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Fig. 2 MPP+ induces an ERK-dependent transcriptional upre-
gulation of TSPO. A Representative WB bands of SH-SY5Y cells
treated with 100 nM Rot for 4, 6, and 8 h. Whole-cell protein lysates
were probed for TSPO and β- actin (ACTB). B Average band densities
were normalised to ACTB, (n= 3). C Representative WB bands of
TSPO and ACTB in SH-SY5Y whole-cell lysates, following admin-
istration of 0.5 mM MPP+ for 8 h, in absence or presence of the MEK
inhibitor U0126. TSPO band densities are given in (D) (n ≥ 6). E The
mRNA levels of both TSPO and 18S ribosomal RNA were measured
by reverse transcription quantitative real-time PCR. TSPO absolute
copy number was normalised over 18S (n= 3). F Representative SDS-
PAGE of wild type SH-SY5Y cells treated (Control) for 8 and 20 h
with 0.5 mM MPP+, immunoprobed for the IMM proteins ATP5B
and SDHA, the OMM protein VDAC1 and the loading control ACTB.
Band density quantification of the expression of (G) ATP5B, (H)
SDHA, (I) VDAC1 normalised to ACTB (n ≥ 3). J, K PI stained-to-
transfected cell ratio of cells treated with MPP+ dosages (0.5 mM for
20 h, 4 mM for 2 h) and expressing different TSPO levels (n= 3).
L Trypan blue assay of Control and −TSPO cells following challenge
with various dopamine concentrations (100, 200, and 300 µM). Results
are presented as the ratio of living cells compared to non-treated.
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Fig. 3 TSPO drives cellular redox-stress response triggered by the
neurotoxin MPP+. A Representative DHE analysis images in ±TSPO
cells transfected with CFP and treated with 4 mM MPP+ in acute
(15 min). B Representative fluorescent traces and (C) linear DHE
increment quantification for cells transfected with TSPO and treated
with MPP+ (n ≥ 15 cells). D Representative images of mitoSOX™
staining of ±TSPO cells co-transfected with CFP and treated with
4 mM MPP+ shortly (15 min) before imaging. E Quantification of
mitochondrial mitoSOX intensity from (D) (n ≥ 20 cells). F DCFDA
analysis of cellular peroxyl radicals in cells transfected for TSPO and
with the DsRed. 4 mMMPP+ treatment carried out for 15 min and (G)
average DCFDA fluorescence count normalised to control (n ≥ 20
cells). H qRT-PCR of Control and +TSPO cells with primers for
human MAOB. Absolute copy numbers were quantified, normalised to
the loading control, the 18S gene, and normalised to transfection
control. (n= 3). I Mitochondrial morphology analysis, using mtGFP,
in ±TSPO cells treated with MPP+ (2 mM) for 4 h. Two mathematical
image-based analyses were made: (J) form factor, a measure of
branching, and (K) aspect ratio, a measure of elongation (n= 10 cells).
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mitophagy pathway. Collectively, these data confirm a role
for TSPO in basal and stress-induced mitochondrial quality
control via de-ubiquitinating mechanisms. However, the
necessity of utilising BAF to detect LC3 recruitment to
mitochondria and MPP+induced ubiquitination implied a
downstream effect on the autophagolysosomal pathway,
which we therefore explored.
Regulation of autophagolysosomal response by
TSPO
Using the live-cell imaging dye LysoTracker™ DND-22 to
mark lysosomes fluorescently, we assayed the lysosomal
population in Control and −TSPO SH-SY5Y cells treated
with MPP+ (0.5 mM, 20 h) (Fig. 5A, B). The results
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indicated that MPP+ induces an increase in lysosomal counts
in control cells, which reached values comparable to those
registered in−TSPO cells at resting conditions. However, this
effect was lost when the MEK-induced phosphorylation of
ERK1/2 pathway was inhibited via UO126. Since the
microphtalmia/trascription factor E (MiT/TFE) family of
transcription factors comprises the most important regulators
of lysosomal turnover [89], we sought to test their involve-
ment, and by using ICC, we assayed the levels and subcellular
localisation of transcription factor EB (TFEB) [90–92]
(Fig. 5C, D). In our experimental system, we found that in
−TSPO cells, the amount of nuclear TFEB increases when
compared to control ones, and so does the number of lyso-
somes and their volume (Supplementary Fig. 2G, H). Being
the expression of TSPO driven by the activation of the ERK
pathway, which is engaged by MPP+ [52] we explored
whether the levels of TSPO affected the degree of pERK1/2
phosphorylation; the data in Fig. 5 panels E, F do confirm that
TSPO does increase the degree of ERK1/2 phosphorylation.
Having observed that MPP+ and TSPO increase global ROS
levels (Fig. 3), we sought to determine whether this effect
could modulate ERK1/2 phosphorylation. Protein kinase Cε
(PKCε) is sensitive to redox status [93] and is known to
phosphorylate ERK1/2 as well as to mediate phorbol myr-
istate acetate (PMA)-induced TSPO upregulation [49, 94].
Therefore, TSPO may control its upstream regulator via a
positive feedback mechanism, relying on oxidative stress.
Furthermore, in keeping with this, the levels of pERK1/2 are
dramatically reduced when TSPO-positive cells are treated
with the antioxidant mitoTEMPO (Fig. 5G, H). In order to
confirm this and corroborate the ample role played by TSPO
on autophagy we mapped the transcriptome of dopaminergic
neurons control (WT) versus those genetically depleted for
TSPO (KO), untreated (UNT), or treated (MPP+) with the
PD neurotoxin of interest. The next generation sequencing
(NGS) analysis portraited a significant variance in the
expression of the relative genes (Fig. 5I, J and Supplementary
Fig. 4G, H) which was further evident among those which
partake in general and selective autophagy (Fig. 5K). The
working model depicted in Fig. 6 therefore proposes TSPO as
required in the pathway to repress selection of mitochondria
and therefore promote the aetiology of the whole network
during neurotoxicity.
Discussion
The role of mitochondria in PD is known for nearly half of a
century [4, 32, 95], but our understanding of their con-
tribution to the disease’s pathogenesis is unresolved. The
mitochondrial decay in faulty dopaminergic neurons
expands beyond the impairments in energy supply and
second messengers (i.e. Ca2+) spanning inter-organelles
communication and quality control mechanisms
[7, 31, 96, 97]. This re-set the focus on mitochondrial
aetiology of PD: 5 out of 18 risk factor genes for PD are
linked to mitophagy (PARK2, PINK1, DJ-1, FBXO7,
HTRA2). The incapacity of removing defective mitochon-
dria through the process of mitophagy reroutes functional
and architectural homeostasis of neurons to deficiencies.
Finding early markers of mitochondrial commitment to PD
is therefore pivotal to pave the way to improved diagnostic
and therapeutic protocols.
In this work, we demonstrate TSPO to be one of those.
Though enrolled to map neuroinflammation in several dis-
eases [22, 98], little is known of TSPO molecular function
in the pathogenesis of the conditions in which it is found
upregulated [99, 100], and in which its ligands mediate
neuroprotection [101]. In mice injected with MPTP (the
pro-drug catalysed by MAO into MPP+ [102]), treatment
with XBD-173 (TSPO ligand) [103] preserves motor
functions and striatal dopaminergic circuits [101]. Our data
show that PD exploits TSPO to establish archetypical
mitochondrial defects of the disease: increased redox stress
(i), impaired mitophagy (ii), and susceptibility to dopamine-
induced cell death (iii).
The heightened basal redox state in TSPO over-
expressing neurons is not only due to the upregulation of
the cytoplasmic NADPH oxidase [60], but also by the
parallel accumulation of MAOB (Fig. 3H), which amplifies
the presence of free radicals [104, 105].
Fig. 4 TSPO represses the MPP+ mediated activation of mito-
phagy. A Mitophagy index measured with mtKeima in mock-trans-
fected, ±TSPO cells treated with vehicle (DMSO), 0.5 mM MPP+ or
20 µM FCCP for 20 h (n ≥ 20 cells). B ICC for ATP5B to label
mitochondria (red) in cells transfected with TSPO siRNA/nsc and
GFP-tagged LC3 and treated with either vehicle (DMSO), 10 nM
Bafilomycin 1A and 0.5 mM MPP+ for 20 h. The average number of
mitochondrial LC3 punctae quantified in (C) (n ≥ 10 cells). D ICC
analysis of Parkin translocation to mitochondria, immunostained for
ATP5B. -TSPO cells transfected with Parkin-YFP, were treated for
20 h with DMSO, 0.5 mM MPP+ or 20 µM FCCP. Percentage of cells
with Parkin punctuation onto mitochondria (n ≥ 20 cells per condition)
were represented in (E). F ICC for ATP5B to label mitochondria (red)
in Control and -TSPO cells GFP-tagged ubiquitin and also treated with
either vehicle (DMSO), 10 nM Bafilomycin 1A and MPP+ (0.5 mM,
20 h). G % of mitochondria co-localised with ubiquitin punctae was
used a measure of mitochondrial ubiquitination. n ≥ 10 cells per con-
dition. H Western blot of mock-transfected cells or overexpressing
TSPO. Whole-cell protein lysates were probed for USP30 and a
mitochondrial marker ATP5B. The blot was quantified in (I) (n= 3).
J mRNA from Control and +TSPO cells was used for a quantitative
reverse transcriptase PCR. The absolute mRNA copy number of
USP30 was extrapolated and normalised to 18S mRNA copy number.
Each +TSPO value was then normalised to its Control (n= 3).
K Representative WB bands of whole-cell protein lysates of WT and
PINK1 KO SH-SY5Y cells probed for PINK1 and β- actin (ACTB).
L mtKeima measurement of mitophagy in nsc or −TSPO PINK1 KO
cells treated with vehicle (DMSO), MPP+ (0.5 mM, 20 h) or FCCP
(20 µM, 20 h). n ≥ 10 cells.
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Fig. 5 Lysosomal homeostasis is impaired by TSPO. A Repre-
sentative images of LysoTracker staining of the lysosomal population
in cells control or -TSPO and treated with vehicle (DMSO), 0.5 mM
MPP+ for 20 h. B Quantification of the total lysosomal number per
cell (n ≥ 20 cells). C Cells transfected with GFP control (nsc) and
−TSPO were immunostained for TFEB following treatment with
vehicle (DMSO), or 0.5 mM MPP+ for 20 h. D Quantification of
TFEB nuclear localisation (n ≥ 15 cells). E Representative bands of
Vinculin, TFEB, TSPO, ERK1/2, and pERK1/2 from WB SDS-PAGE
of whole-cell lysates of Control (wt) and -TSPO cells. Average band
density of (F) pERK1/2 normalised to ERK1/2 and to respective
Control (n= 3). Representative images of pERK1/2 ICC in wild type
cells treated with 20 µM mitoTEMPO (G). H Quantification of ERK1/
2 phosphorylation via image-based analysis of pERK1/2 area over cell
area (n= 20 cells). I Principal component analysis of RNAseq data
from Control and -TSPO cells. Heat maps in (J and K) are respectively
of the full genome and genes involved in the cell’s quality control
regulation.
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Interestingly, the absence of an MPP+induced spike of
ROS in +TSPO cells indicates that neurons rich in TSPO
retain higher levels of reduced GSH, which is consumed
following MPP+ administration (Supplementary Fig. 1E–G).
Therefore, we speculate that the excess of GSH reacts with
the additional ROS preventing further and detrimental burst.
In +TSPO cells, the greater GSH level may originate from
the inhibition of Keap1, which would allow for the Nuclear
factor erythroid 2-related factor 2 (Nrf2) to migrate to the
nucleus and upregulate the synthesis of GSH [106, 107]. The
Nrf2 pathway is indeed responsible for the increased pro-
duction of GSH s-transferase that executes the rate-limiting
step in GSH production in the cytoplasm [108–110]. This
was previously confirmed pharmacologically via the pro-
mitophagic drug PMI which represses TSPO [111].
The ability of TSPO to increase redox signalling while
leaving unaltered the antioxidant pools would also explain
why +TSPO cells resist cell death caused by a higher
concentration of MPP+ and excessive dopamine level
(Fig. 2K, L) besides preventing the exacerbation of the
MPP+induced oxidative stress (Fig. 3D, E, S). Accord-
ingly, cells devoid of TSPO (−TSPO) undergo extensive
ΔΨm depolarisation following treatment with MPP+
(Supplementary Fig. 2A–F), being at the same time more
susceptible to death induced by the toxin (Fig. 2K) but not
to the one caused by dopamine (Fig. 2L); indicative of an
ongoing selection of defective mitochondria selection by
mitophagy in these cells. And the analysis of mitochon-
drial morphology did reveal a more elongated and
branched network of mitochondria in -TSPO cells corre-
sponding to more favourable bioenergy [112, 113] as
witnessed by the higher basal ΔΨm (Supplementary
Fig. 2A–E).
Both 6-OHDA or MPP+ trigger the MAPK/ERK path-
way, which drives the expression of TSPO. This establishes
a feedback loop for which ERK is continuously active -by
the high degree of oxidative stress- repressing the retro-
translocation of TFEB to the nucleus and so the overall
autophagy response by the repressed production of lyso-
somes (Figs. 4, 5).
Though deficiencies in lysosomal homeostasis could also be
contributed by the impaired Ca2+ homeostasis driven by
TSPO, the persistent level of free radicals of the oxygens in the
cytosol (i) and the very nature of the trigger (MPP+) which
engages the MAPK signalling (ii) suggest alterations in the
TFEB transcriptional capacity to be the driving mechanism.
Fig. 6 Model on TSPO role in
the etiopathogenesis of
neurotoxicity. The addition of







Concomitantly, it induces redox
stress to promote ERK1/2
phosphorylation and
modifications in the dynamics of
the autophagolysosomal
pathways.
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Nuclear TFEB, an essential transcription factor for the
completion of the autophagolysosomal pathway [90, 114],
is upregulated in -TSPO cells and during challenge with PD
toxins (Fig. 5). This made us propose that MPP+ {and
therefore the neurotoxins capable of recapitulating the dis-
ease [68, 69, 115]} activate mitophagy by stimulating
TFEB, which is negatively regulated by the concomitant
overexpression of TSPO (Fig. 5). The transcriptome data
well corroborate that loss of TSPO in neurons is pivotal to
several genetic alterations, which are exploited further by
the treatment with the neurotoxin MPP+ (Fig. 5 and Sup-
plementary Fig. 4G, H). The limited availability of autop-
hagosomes and production of lysosomes (Fig. 5) aligns with
the deubiquitylation of mitochondria perpetrated by TSPO.
Mitophagy occurs if de-ubiquitinating molecules such as
USP30 are inhibited [88]. TSPO, on the contrary, stabilises
USP30, thereby impeding the processing of mitochondrial
proteins required for the completion of the pathway
(Fig. 4H, I). USP30 has been considered a therapeutic target
since the discovery of its involvement in mitophagy [46],
whereas its inhibition rescues motor symptoms and lifespan
of PD Drosophila models. The recent publications of three
proteomic studies [44, 45, 116] have highlighted that
changes in the ubiquitylome at appropriate dosages faith-
fully replicate the genetic ablation of USP30, which none-
theless remains particularly hostile to target with chemicals.
TSPO could therefore offer an alternative site for therapeutic
inferring of USP30, and advantages for this approach stem
from the extensively studied pharmacodynamic and phar-
macokinetic properties of its ligands [17, 20, 117].
It is known that the monogenic forms of the disease
constitute only 5–10% of the total PD cases [118, 119],
demanding for a greater understanding of the aetiological
factors at the basis of the sporadic forms, which account for
the greatest portion of cases. TSPO merges as a potential
target to inform and control both onset and penetrance.
Though its anti-mitophagic role will intensify the retro-
communication with nucleus [120] to favour cell survival,
this beneficial effect will be short-lived as TSPO-positive
neurons will succumb to dopamine toxicity in the long-term
(Fig. 2L and Supplementary Fig. 4A–F).
Importantly the upregulation of TSPO in response to
neurotoxins is selective for neurons as microglial cells are
unresponsive to PD toxins (Supplementary Fig. 3A, B).
In light of these data, it is not surprising that direct
detection of the protein in mice and in vivo PET measure-
ments demonstrate higher TSPO expression with aging
[60, 121], which is per se a demonstrated risk factor for the
development and progression of Parkinson’s disease (PD).
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